2024 ICD-10-CM Diagnosis Code T42.8X1A

Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, accidental (unintentional), initial encounter

ICD-10-CM Code:
T42.8X1A
ICD-10 Code for:
Poisn by antiparkns drug/centr musc-tone depr, acc, init
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Not chronic
Code Navigator:

Code Classification

  • Injury, poisoning and certain other consequences of external causes
    (S00–T88)
    • Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
      (T36-T50)
      • Poisoning by, adverse effect of and underdosing of antiepileptic, sedative- hypnotic and antiparkinsonism drugs
        (T42)

T42.8X1A is a billable diagnosis code used to specify a medical diagnosis of poisoning by antiparkinsonism drugs and other central muscle-tone depressants, accidental (unintentional), initial encounter. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024.

T42.8X1A is an initial encounter code, includes a 7th character and should be used while the patient is receiving active treatment for a condition like poisoning by antiparkinsonism drugs and other central muscle-tone depressants accidental (unintentional). According to ICD-10-CM Guidelines an "initial encounter" doesn't necessarily means "initial visit". The 7th character should be used when the patient is undergoing active treatment regardless if new or different providers saw the patient over the course of a treatment. The appropriate 7th character codes should also be used even if the patient delayed seeking treatment for a condition.

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Accidental amantadine overdose
  • Accidental baclofen overdose
  • Accidental bromocriptine overdose
  • Accidental bromocriptine poisoning
  • Accidental ergot alkaloid overdose
  • Accidental ergot alkaloid overdose
  • Accidental ergot alkaloid poisoning
  • Accidental ergot alkaloid poisoning
  • Accidental ergot alkaloid poisoning
  • Accidental ergot alkaloid poisoning
  • Accidental levodopa overdose
  • Accidental levodopa poisoning
  • Accidental lysuride overdose
  • Accidental lysuride poisoning
  • Accidental methocarbamol overdose
  • Accidental poisoning by amantadine
  • Accidental poisoning by carbamates
  • Accidental poisoning by carbamic ester
  • Accidental selegiline overdose
  • Accidental selegiline poisoning
  • Amantadine overdose
  • Antiviral drug overdose
  • Antiviral drug overdose
  • Baclofen overdose
  • Bromocriptine overdose
  • Bromocriptine poisoning
  • Carbamate overdose
  • Decarboxylase inhibitor overdose
  • Decarboxylase inhibitor poisoning
  • Levodopa overdose
  • Lysuride overdose
  • Lysuride poisoning
  • Mephenesin poisoning
  • Methocarbamol overdose
  • Methocarbamol poisoning
  • Poisoning by amantadine
  • Poisoning by levodopa
  • Poisoning caused by chlorphenesin
  • Selegiline overdose
  • Selegiline poisoning
  • Skeletal muscle relaxant overdose

Clinical Classification

Clinical CategoryCCSR Category CodeInpatient Default CCSROutpatient Default CCSR
External cause codes: intent of injury, accidental/unintentionalEXT020N - Not default inpatient assignment for principal diagnosis or first-listed diagnosis.N - Not default outpatient assignment for principal diagnosis or first-listed diagnosis.
External cause codes: poisoning by drugEXT014N - Not default inpatient assignment for principal diagnosis or first-listed diagnosis.N - Not default outpatient assignment for principal diagnosis or first-listed diagnosis.
Poisoning by drugs, initial encounterINJ022Y - Yes, default inpatient assignment for principal diagnosis or first-listed diagnosis.Y - Yes, default outpatient assignment for principal diagnosis or first-listed diagnosis.

Clinical Information

  • Amantadine

    an antiviral that is used in the prophylactic or symptomatic treatment of influenza a. it is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. the mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.
  • Baclofen

    a gamma-aminobutyric acid derivative that is a specific agonist of gaba-b receptors. it is used in the treatment of muscle spasticity, especially that due to spinal cord injuries. its therapeutic effects result from actions at spinal and supraspinal sites, generally the reduction of excitatory transmission.
  • Receptors, GABA-B

    a subset of gaba receptors that signal through their interaction with heterotrimeric g-proteins.
  • Benserazide

    an inhibitor of dopa decarboxylase that does not enter the central nervous system. it is often given with levodopa in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. it has no antiparkinson actions when given alone.
  • Bromocriptine

    a semisynthetic ergotamine alkaloid that is a dopamine d2 agonist. it suppresses prolactin secretion.
  • Cabergoline

    an ergoline derivative and dopamine d2-agonist that inhibits prolactin secretion. it is used in the management of hyperprolactinemia, and to suppress lactation following childbirth for medical reasons. cabergoline is also used in the management of parkinson disease.
  • Carisoprodol

    a centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. it is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (from martindale, the extra pharmacopoeia, 30th ed, p1202)
  • Chlorphenesin

    a centrally acting muscle relaxant. its mode of action is unknown. (from martindale, the extra pharmacopoeia, 30th ed, p1203)
  • Chlorzoxazone

    a centrally acting central muscle relaxant with sedative properties. it is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (from martindale, the extra pharmacopoea, 30th ed, p1202)
  • Dantrolene

    skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in the muscle fiber. it is used in spasticity and other neuromuscular abnormalities. although the mechanism of action is probably not central, dantrolene is usually grouped with the central muscle relaxants.
  • Levodopa

    the naturally occurring form of dihydroxyphenylalanine and the immediate precursor of dopamine. unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. it is rapidly taken up by dopaminergic neurons and converted to dopamine. it is used for the treatment of parkinsonian disorders and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.
  • Lisuride

    an ergot derivative that acts as an agonist at dopamine d2 receptors (dopamine agonists). it may also act as an antagonist at dopamine d1 receptors, and as an agonist at some serotonin receptors (serotonin receptor agonists).
  • Mephenesin

    a centrally acting muscle relaxant with a short duration of action.
  • Metergoline

    a dopamine agonist and serotonin antagonist. it has been used similarly to bromocriptine as a dopamine agonist and also for migraine disorders therapy.
  • Methocarbamol

    a centrally acting muscle relaxant whose mode of action has not been established. it is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (from martindale, the extra pharmacopoeia, 30th ed, p1206)
  • Pergolide

    a long-acting dopamine agonist which has been used to treat parkinson disease and hyperprolactinemia but withdrawn from some markets due to potential for heart valve diseases.
  • Piribedil

    a dopamine d2 agonist. it is used in the treatment of parkinson disease, particularly for alleviation of tremor. it has also been used for circulatory disorders and in other applications as a d2 agonist.
  • Selegiline

    a selective, irreversible inhibitor of type b monoamine oxidase that is used for the treatment of newly diagnosed patients with parkinson disease, and for the treatment of depressive disorders. the compound without isomeric designation is deprenyl.
  • Zoxazolamine

    a uricosuric and muscle relaxant. zoxazolamine acts centrally as a muscle relaxant, but the mechanism of its action is not understood.

Coding Guidelines

When coding a poisoning or reaction to the improper use of a medication (e.g., overdose, wrong substance given or taken in error, wrong route of administration), first assign the appropriate code from categories T36-T50. The poisoning codes have an associated intent as their 5th or 6th character (accidental, intentional self-harm, assault and undetermined. If the intent of the poisoning is unknown or unspecified, code the intent as accidental intent. The undetermined intent is only for use if the documentation in the record specifies that the intent cannot be determined. Use additional code(s) for all manifestations of poisonings.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of antiepileptic, sedative- hypnotic and antiparkinsonism drugs (T42). Use the following options for the aplicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Convert T42.8X1A to ICD-9-CM

  • ICD-9-CM Code: 966.4 - Pois-anti-parkinson drug
    Combination Flag - Multiple codes are needed to describe the source diagnosis code. Correct coding should be done based on contextual judgment.
  • ICD-9-CM Code: 968.0 - Pois-cns muscle depress
    Combination Flag - Multiple codes are needed to describe the source diagnosis code. Correct coding should be done based on contextual judgment.
  • ICD-9-CM Code: E855.0 - Acc poisn-anticonvulsant
    Combination Flag - Multiple codes are needed to describe the source diagnosis code. Correct coding should be done based on contextual judgment.

Table of Drugs and Chemicals

The parent code T42.8X1 of the current diagnosis code is referenced in the Table of Drugs and Chemicals, this table contains a classification of drugs, industrial solvents, corrosive gases, noxious plants, pesticides, and other toxic agents.

According to ICD-10-CM coding guidelines it is advised to do not code directly from the Table of Drugs and Chemicals, instead always refer back to the Tabular List when doing the initial coding. Each substance in the table is assigned a code according to the poisoning classification and external causes of adverse effects. It is important to use as many codes as necessary to specify all reported drugs, medicinal or chemical substances. If the same diagnosis code describes the causative agent for more than one adverse reaction, poisoning, toxic effect or underdosing, utilize the code only once.

Substance Poisoning
Accidental
(unintentional)
Poisoning
Accidental
(self-harm)
Poisoning
Assault
Poisoning
Undetermined
Adverse
effect
Underdosing
AfloqualoneT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
AmantadineT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
Antiparkinsonism drug NECT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
Antirigidity drug NECT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
BaclofenT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
BenserazideT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
BenzatropineT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
BromocriptineT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
CabergolineT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
Carbidopa (with levodopa)T42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
CarisoprodolT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
ChlorphenesinT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
Chlorphenesin
  »topical (antifungal)
T42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
ChlorzoxazoneT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
DantroleneT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
DeprenalinT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
DeprenylT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
DiethazineT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
DifluoromethyldopaT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
DisipalT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
DopaT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
IdrocilamideT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
L-dopaT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
LevodopaT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
Levodopa
  »with carbidopa
T42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
LisurideT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
Mephenamin (e)T42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
MephenesinT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
MephenoxaloneT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
MesulergineT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
MetaxaloneT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
MetergolineT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
MethocarbamolT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
Methocarbamol
  »skeletal muscle relaxant
T42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
Muscle-tone depressant, central NECT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
Muscle-tone depressant, central NEC
  »specified NEC
T42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
Orphenadrine (hydrochloride)T42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
PergolideT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
PhenprobamateT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
PiribedilT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
RelaT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
SelegilineT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
SomaT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
StyramateT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
TizanidineT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
TolserolT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6
ZoxazolamineT42.8X1T42.8X2T42.8X3T42.8X4T42.8X5T42.8X6

Patient Education


Medication Errors

Medicines treat infectious diseases, prevent problems from chronic diseases, and ease pain. But medicines can also cause harmful reactions if not used correctly. Errors can happen in the hospital, at the health care provider's office, at the pharmacy, or at home. You can help prevent errors by:

  • Knowing your medicines. When you get a prescription, ask the name of the medicine and check to make sure that the pharmacy gave you the right medicine. Make sure that you understand how often you should take the medicine and how long you should take it.
  • Keeping a list of medicines.
    • Write down all of the medicines that you are taking, including the names of your medicines, how much you take, and when you take them. Make sure to include any over-the-counter medicines, vitamins, supplements, and herbs that you take.
    • List the medicines that you are allergic to or that have caused you problems in the past.
    • Take this list with you every time you see a health care provider.
  • Reading medicine labels and following the directions. Don't just rely on your memory - read the medication label every time. Be especially careful when giving medicines to children.
  • Asking questions. If you don't know the answers to these questions, ask your health care provider or pharmacist:
    • Why am I taking this medicine?
    • What are the common side effects?
    • What should I do if I have side effects?
    • When should I stop this medicine?
    • Can I take this medicine with the other medicines and supplements on my list?
    • Do I need to avoid certain foods or alcohol while taking this medicine?

Food and Drug Administration


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.